GleamWall
中文EN

OPK OPKO HEALTH, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 944809 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-8.3%
TTM net income YoY17.9%
TTM EPS YoY24.0%
Revenue 3-yr CAGR-16.7%
Net income 3-yr CAGR—

Margins

Gross margin46.2%
Operating margin-25.5%
Net margin-29.5%
FCF margin-27.0%
EBITDA margin-8.3%

Returns

ROE-12.2%
ROA-7.6%
ROIC (approx.)-12.4%
Asset turnover0.26x

Leverage & solvency

Liabilities / assets40.6%
Debt / equity0.00x
Current ratio4.97x
Interest coverage2.08x

Cash quality & payout

Operating cash flow / net income0.84x
Accruals ratio-1.2%
Payout ratio—
Capex / revenue2.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q42025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q42024-12-31
Income statement
Revenue$65.41M$163.58M$124.20M$148.45M$56.42M$156.81M$149.95M$183.64M
Cost of revenue$23.35M$83.56M$78.44M$84.42M$21.37M$107.41M$107.33M$98.98M
Gross profit$42.06M$80.02M$45.76M$64.03M$35.05M$49.40M$42.62M$84.66M
R&D expense$32.18M$33.17M$29.20M$32.77M$29.80M$30.34M$30.84M$30.43M
SG&A expense$24.84M$52.92M$48.61M$50.52M$22.27M$59.60M$59.09M$67.03M
Operating income-$31.41M-$6.97M-$51.02M-$38.32M-$33.55M-$59.98M-$67.17M-$33.14M
Interest expense$13.45M$11.38M$10.94M-$97.03M$11.33M$70.33M$15.47M$14.24M
Pretax income-$42.87M-$13.40M-$60.96M-$3.29M-$40.97M-$162.52M-$73.37M$34.98M
Income tax-$7.31M-$4.98M-$6.11M-$15.66M-$8.05M-$14.08M-$5.77M$20.95M
Net income-$53.53M-$8.42M-$54.85M-$31.26M$21.63M-$148.44M-$67.61M$14.03M
EBITDA-$12.47M$15.44M-$28.82M-$15.94M-$15.51M-$36.95M-$43.68M-$9.10M
EPS (basic)-0.07-0.01-0.07-0.040.03-0.19-0.100.02
EPS (diluted)-0.07-0.01-0.07-0.040.03-0.19-0.100.01
Weighted avg. shares (diluted)746.48M755.27M758.88M—777.15M788.01M671.58M—
Balance sheet
Cash & equivalents$384.04M$300.76M$331.86M$364.41M$411.97M$267.28M$428.83M$426.58M
Receivables$80.21M$81.89M$79.64M$90.25M$94.58M$99.38M$96.15M$118.02M
Inventory$50.60M$61.85M$64.40M$52.73M$64.95M$66.34M$64.00M$56.80M
Current assets$806.28M$500.24M$535.36M$581.88M$627.13M$583.33M$737.60M$662.09M
PP&E, net$68.02M$71.45M$72.58M$72.81M$74.99M$74.94M$71.19M$70.13M
Goodwill$317.36M$481.51M$482.27M$320.85M$484.03M$484.19M$476.67M$529.25M
Intangibles$396.17M$477.57M$496.35M$446.43M$535.38M$555.99M$568.52M$616.61M
Total assets$1.88B$1.83B$1.86B$1.93B$2.00B$1.97B$2.13B$2.20B
Current liabilities$162.36M$149.37M$148.38M$146.68M$169.32M$171.18M$295.85M$193.10M
Short-term debt$1.19M$912,000$1.53M$1.74M$1.46M$1.52M$1.43M$437.20M
Long-term debt$1.56M$1.78M$2.01M$2.26M$2.51M$2.77M$2.83M$3.00M
Total debt$2.75M$2.69M$3.54M$4.00M$3.97M$4.29M$4.26M$440.20M
Total liabilities$764.08M$645.29M$652.19M$663.98M$690.02M$676.09M$816.66M$834.76M
Shareholders' equity$1.12B$1.18B$1.20B$1.27B$1.31B$1.30B$1.31B$1.37B
Net debt-$381.28M-$298.07M-$328.33M-$360.41M-$408.00M-$262.99M-$424.57M$13.62M
Cash flow statement
Operating cash flow-$36.31M-$43.50M-$19.31M-$25.92M-$34.65M-$83.42M-$34.55M-$44.41M
Capital expenditure$2.79M$3.00M$1.83M$2.67M$3.13M$3.28M$3.19M$5.41M
Free cash flow-$39.10M-$46.50M-$21.14M-$28.59M-$37.78M-$86.70M-$37.75M-$49.82M
Investing cash flow$11.29M$15.54M-$1.80M-$2.05M$194.65M-$2.83M$40.53M$115.99M
Financing cash flow$114.47M-$13.03M-$5.16M-$18.34M-$16.21M-$79.49M-$4.02M-$40.47M
Depreciation & amortization$18.94M$22.41M$22.20M$22.37M$18.04M$23.03M$23.49M$24.04M
Stock-based compensation$1.80M$2.20M$2.73M$2.92M$2.50M$2.20M$2.62M$3.06M
Share buybacks$10.63M$13.02M$4.77M$13.51M$15.28M$18.25M$0$16.46M

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.